Saturday, October 03, 2020 10:18:33 AM
The risk/reward ratio here is actually quite appealing given the LATE STAGES OF DEVELOPMENT both companies are in with respect to their potential HIV cures . . .
Throw in the fact that BioClonetics are legitimate pioneers in the discovery and development of MONOCLONAL ANTIBODIES and you have a perfect storm. The 2 studies which Dr. Fauci used to tout MONOCLONAL ANTIBODIES as "the most promising" potential cure for Covid came out just LAST WEEK. This is fresh. Gotta stay ahead of the game.
Trump is taking MONOCLONAL ANTIBODIES shows that this is the best possible treatment at this moment in time and funding for advacements/development will be flowing in. I read a ton of academic literature last night on MONOCLONAL ANTIBODIES in which the Cotropia Bros are cited as authorities. They will be involved with developing a Covid cure utilizing MONOCLONAL ANTIBODIES without a doubt. Stay ahead!
Hedge Funds look for 30-100 Baggers. At these levels, the risk/reward ratio is there for someone willing to do the research.
Recent ENZC News
- Small Cap Recipient of Military Drone Technology • InvestorsHub NewsWire • 11/20/2023 01:14:45 PM
North Bay Resources Announces Composite Assays of 0.53 and 0.44 Troy Ounces per Ton Gold in Trenches B + C at Fran Gold, British Columbia • NBRI • Jun 18, 2024 9:18 AM
VAYK Assembling New Management Team for $64 Billion Domestic Market • VAYK • Jun 18, 2024 9:00 AM
Fifty 1 Labs, Inc Announces Acquisition of Drago Knives, LLC • CAFI • Jun 18, 2024 8:45 AM
Hydromer Announces Attainment of ISO 13485 Certification • HYDI • Jun 17, 2024 9:22 AM
ECGI Holdings Announces LOI to Acquire Pacific Saddlery to Capitalize on $12.72 Billion Market Potential • ECGI • Jun 13, 2024 9:50 AM
Fifty 1 Labs, Inc. Announces Major Strategic Advancements and Shareholder Updates • CAFI • Jun 13, 2024 8:45 AM